A 12-week safety study of Cannabinoid-Infused Topical Cream for the treatment of psoriasis and related skin conditions in healthy volunteers.
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Nabiximols (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- 27 Feb 2017 Status changed from planning to recruiting, as reported by an OWC Pharmaceutical media release.
- 27 Feb 2017 According to an OWC Pharmaceutical media release, company has received Institutional Review Board (IRB) approval to conduct this trial. This study will be included in NIH Registry.
- 29 Nov 2016 New trial record